By Nascent Biotech Posted April 4, 2018 In HAH 2018 2pp CFP Leaflet copy2018-04-042018-04-04http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 Recent PostsNascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug ConjugatesNascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under ValuedNascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution RiskMarble Arch Research: What is Pritumumab and How it Works